Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Microglia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Microglia. Displaying page 1 of 1.
    EudraCT Number: 2016-003529-41 Sponsor Protocol Number: ABR58805 Start Date*: 2017-02-22
    Sponsor Name:University Medical Center Utrecht
    Full Title: CANGLIA: Endocannabinoid control of microglia activation as a new therapeutic target in the treatment of schizophrenia
    Medical condition: Schizophrenia patients
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-004328-40 Sponsor Protocol Number: INMINDFP7-HEALTH-2011-two-stage Start Date*: 2013-03-01
    Sponsor Name:OSPEDALE S. RAFFAELE DI MILANO
    Full Title: IMAGING OF NEUROINFLAMMATION IN NEURODEGENERATIVE DISEASES
    Medical condition: mild cognitive impairment, Alzheimer disease,frontotemporal dementia, SLA
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004848 10050727 RI scan LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004803-19 Sponsor Protocol Number: D0490C00004 Start Date*: 2012-02-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIA, Multi centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Effect of 8 Weeks Treatment with Oral AZD3241 on Microglia Activation, as Measured by Pos...
    Medical condition: Parkinson's Disease; Microglia activation as measured by [11C]PBR28 binding to TSPO
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2014-004448-37 Sponsor Protocol Number: PET-CFS-1 Start Date*: 2015-09-30
    Sponsor Name:University Medical Center Groningen
    Full Title: Visualising neuroinflammation in chronic fatigue syndrome patients
    Medical condition: Chronic Fatigue Syndrome
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004902-13 Sponsor Protocol Number: D0490C00023 Start Date*: 2015-04-09
    Sponsor Name:AstraZeneca AB
    Full Title: A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positr...
    Medical condition: Multiple system atrophy (MSA)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10064060 Multiple system atrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001206-24 Sponsor Protocol Number: 16901 Start Date*: 2007-07-31
    Sponsor Name:UMCG
    Full Title: Effect of selective COX-2 inhibition on neuroinflammation in Parkinson's disease
    Medical condition: Parkinson's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001179-21 Sponsor Protocol Number: 11-EI-0263 Start Date*: 2018-01-17
    Sponsor Name:The National Eye Institute
    Full Title: A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Branch Retinal Vein Occlusions
    Medical condition: Branch Retinal Vein Occlusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-001143-12 Sponsor Protocol Number: 11-EI-0264 Start Date*: 2018-01-09
    Sponsor Name:The National Eye Institute
    Full Title: A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Central Retinal Vein Occlusions
    Medical condition: Central Retinal Vein Occlusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-001542-17 Sponsor Protocol Number: T109/2019Xe-SAH Start Date*: 2020-09-17
    Sponsor Name:Timo Laitio
    Full Title: Effect of xenon on brain injury, neurological outcome and survival in patients after aneurysmal subarachnoid hemorrhage
    Medical condition: Acute rupture of cerebral aneurysm, subarachnoid hemorrhage (SAH), unconsciousness, brain injury.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10008078 Cerebral arterial aneurysm LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005162-33 Sponsor Protocol Number: RF-2018-12365308 Start Date*: 2022-11-08
    Sponsor Name:IRCCS CENTRO SAN GIOVANNI DI DIO - FATEBENEFRATELLI AFFERENTE ALLA PROVINCIA LOMBARDO VENETA ORDINE OSPEDALIERO DI SAN G
    Full Title: Targeting inflammation in depression using minocycline: a patient stratification approach using peripheral inflammatory biomarkers, PET and MRI
    Medical condition: depressed patients with high levels of inflammation (crp>2 mg/l) and non responder to at least two different antidepressants
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002672-12 Sponsor Protocol Number: 73807 Start Date*: 2020-12-11
    Sponsor Name:Erasmus Medical Center
    Full Title: Frontotemporal dementia Imaging of Neuroinflammation, Degeneration and Microglia-Related Effects
    Medical condition: Frontotemporal dementia (FTD), including symptomatic patients and presymptomatic individuals with genetic mutations predisposing to FTD at a later stage in life.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003622-16 Sponsor Protocol Number: T214/2016 Start Date*: 2017-09-19
    Sponsor Name:Turku University Hospital
    Full Title: Targeting SPMS: Effect of teriflunomide treatment on microglial activation in an MS patient cohort at risk of progression. A [11C]PK11195 Brain PET study.
    Medical condition: Multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004415-24 Sponsor Protocol Number: 09/2011MolecularImaging Start Date*: 2012-01-16
    Sponsor Name:IRCCS CENTRO SAN GIOVANNI DI DIO
    Full Title: Molecular imaging for the early diagnosis and monitoring of Alzheimer’s disease in old individuals with cognitive disturbances: an ADNI-compatible prospective study
    Medical condition: Mild Congitive Impairment (MCI)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10050727 RI scan LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002987-57 Sponsor Protocol Number: AL002-LTE Start Date*: 2023-03-09
    Sponsor Name:Alector Inc.
    Full Title: A Multicenter, Long-Term Extension Study to Evaluate the Safety, Tolerability, and Efficacy of AL002 in Participants with Alzheimer’s Disease
    Medical condition: Early Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005947-22 Sponsor Protocol Number: SIPO20 Start Date*: 2021-11-17
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
    Full Title: Effect of siponimod on relevant imaging and immunological hallmarks of progressive multiple sclerosis
    Medical condition: Active progressive MS course after an initial relapse clinical course
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10053395 Progressive multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2023-000018-16 Sponsor Protocol Number: OZA22/IM047-048 Start Date*: 2023-04-19
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
    Full Title: Effect of ozanimod on meningeal inflammation and glial activation in Multiple Sclerosis: one year phase 4 experimental study
    Medical condition: Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005755-20 Sponsor Protocol Number: ALZ-801-AD301 Start Date*: 2021-06-21
    Sponsor Name:Alzheon, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer's Disease and APOE4/4 Genotype
    Medical condition: Early Alzheimer’s Disease (AD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001897 Alzheimer's disease (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) NL (Completed) ES (Completed) CZ (Completed) IS (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000826-22 Sponsor Protocol Number: CBLZ945C12201 Start Date*: 2019-09-17
    Sponsor Name:Novartis Pharma AG
    Full Title: An open-label, adaptive design study in patients with amyotrophic lateral sclerosis (ALS) to characterize safety, tolerability and brain microglia response, as measured by TSPO binding, following m...
    Medical condition: Amyotrophic lateral sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000986-17 Sponsor Protocol Number: ALZ-801-201ADBM Start Date*: 2020-09-11
    Sponsor Name:Alzheon Inc.
    Full Title: A Phase 2, Single Arm, Study of the Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer’s Disease Who Are Carriers of the ε4 Variant of the Apolipoprotein E Gene (APOE4/4 or APOE3/4)
    Medical condition: Subjects with a clinical diagnosis of Alzheimer's disease who are APOE 4 carriers (APOE4/4, APOE3/4) and at the Early stage of disease, ages 50-80 years
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001476-11 Sponsor Protocol Number: AL002-2 Start Date*: 2020-11-12
    Sponsor Name:Alector Inc.
    Full Title: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AL002 IN PARTICIPANTS WITH EARLY ALZHEIMER’S DISEASE
    Medical condition: Early Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) PL (Completed) DE (Completed) IT (Completed) FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 06:06:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA